SLXN

Profile

Full Name

Silexion Therapeutics Corp

Ticker Symbol

SLXN

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

Israel

IPO

August 16, 2024

Indexes

Not included

Website

http://silexion.com

Employees

-

Key Details

Price

$0.77(-2.41%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$26.36(-383.11% YoY)

PE ratio

-

Next earnings date

N/A

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.77
SLXN price is $0.77

30-Day Relative Volume

0.18
SLXN 30-day relative volume is 0.18

Price Performance

Price Most recent change

-2.41%
SLXN price was down -2.41% on Apr 16, 2025

Price YTD change

-61.64%
SLXN price is down -61.64% since January 1st

Price 1-year change

-93.13%
SLXN price is down -93.13% year-on-year

Price 3-year change

-92.15%
SLXN price is down -92.15% over the past 3 years

Price Range

Price All-time high

$13.56
SLXN price is currently -94.31% below its historical high of $13.56

Price 3-year low

$0.21
SLXN price is currently +272.46% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$6.70M
SLXN market capitalization is $6.70 million

Market cap 3-year change

-
SLXN market capitalization 3-year change is unknown

Market cap All-time high

$12.12M
SLXN market capitalization is currently -44.69% below its historical high of $12.12 million

Market cap sector rank

15.87%
SLXN market capitalization is higher than 15.87% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

-
SLXN shares outstanding 1-year change is unknown

Shares Outstanding 3-Year Change

-
SLXN shares outstanding 3-year change is unknown

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

2.61
SLXN beta is 2.61

200-day SMA

$2.93
SLXN price is currently -73.67% below its 200-day simple moving average

50-day SMA

$1.11
SLXN price is currently -30.31% below its 50-day simple moving average

RSI

36.59
SLXN 14-day relative strength index is 36.59

Volume

0.18
SLXN 30-day relative volume is 0.18

ATR

$0.11
SLXN average true range is $0.11

10-day Historical Volatility

123.48%
SLXN 10-day historical volatility is 123.48%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
SLXN annual revenue value is unknown

Revenue Analysts estimate

-
SLXN annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
SLXN annual revenue 1-year change is unknown

Revenue Sector rank

-
SLXN annual revenue is unknown

EPS

EPS

-$26.36
SLXN annual earnings per share is -$26.36

EPS Analysts estimate

-$0.64
SLXN annual earnings per share is currently +4018.75% higher than the consensus analysts' forecast

EPS 1-year change

-383.11%
SLXN annual earnings per share is down -383.11% year-on-year

EPS Sector rank

5.7%
SLXN annual earnings per share is higher than 5.7% of companies in Healthcare sector

Profit

Gross profit

-
SLXN annual gross profit value is unknown

Gross margin

-
SLXN annual gross profit margin value is unknown

Operating profit

-$12.57M
SLXN annual operating income is -$12.57 million

Operating margin

-
SLXN annual operating profit margin value is unknown

Net income

-$16.44M
SLXN annual net profit is -$16.44 million

Net margin

-
SLXN annual net profit margin value is unknown

Expenses

Total expenses

$12.57M
SLXN annual total expenses is $12.57 million

Operating expenses

$12.57M
SLXN annual total operating expenses is $12.57 million

Cost of goods sold

-
SLXN annual cost of goods sold value is unknown

Selling, general & administrative expenses

$6.73M
SLXN annual SGA is $6.73 million

Depreciation and amortization

$25.00K
SLXN annual depreciation & amortization is $25.00 thousand

Interest expense

$7000.00
SLXN annual interest expense is $7000.00

Income tax

$10.00K
SLXN annual income tax is $10.00 thousand

EBIT & EBITDA

EBIT

-$16.50M
SLXN annual earnings before interest & taxes is -$16.50 million

EBITDA

-$16.48M
SLXN annual EBITDA is -$16.48 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$2.86M
SLXN annual total assets is $2.86 million

Non current assets

$613.00K
SLXN annual long term assets is $613.00 thousand

Current assets

$2.25M
SLXN annual total current assets is $2.25 million

Cash and cash equivalents

$1.19M
SLXN annual cash & cash equivalents is $1.19 million

Accounts receivable

-
SLXN annual accounts receivable value is unknown

Inventory

-
SLXN annual inventory value is unknown

Liabilities

Total liabilities

$6.85M
SLXN annual total liabilities is $6.85 million

Long term liabilities

$3.33M
SLXN annual total long term liabilities is $3.33 million

Current liabilities

$3.52M
SLXN annual total current liabilities is $3.52 million

Accounts payable

$929.00K
SLXN annual accounts payable is $929.00 thousand

Debt

Total debt

$4.49M
SLXN annual total debt is $4.49 million

Total debt 1-year change

+2526.32%
SLXN annual total debt is up +2526.32% year-on-year

Long term debt

$3.33M
SLXN annual long term debt is $3.33 million

Short term debt

$1.16M
SLXN annual short term debt is $1.16 million

Equity & Capital

Shareholders equity

-$3.99M
SLXN annual stockholders equity is -$3.99 million

Book value

-$3.99M
SLXN annual book value is -$3.99 million

Retained earnings

-$43.25M
SLXN annual retained earnings is -$43.25 million

Working capital

-$1.27M
SLXN annual working capital is -$1.27 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$8.40M
SLXN annual cash flow from operations is -$8.40 million

Cash from operations 1-year change

-85.38%
SLXN annual cash flow from operations is down -85.38% year-on-year

Cash from investing

-$22.00K
SLXN annual cash flow from investing activities is -$22.00 thousand

Cash from investing 1-year change

-103.84%
SLXN annual cash flow from investing activities is down -103.84% year-on-year

Cash from financing

$5.10M
SLXN annual cash flow from financing activities is $5.10 million

Cash from financing 1-year change

+877.78%
SLXN annual cash flow from financing activities is up +877.78% year-on-year

CAPEX

CAPEX

-
SLXN annual capital expenditures value is unknown

CAPEX 1-year change

-
SLXN annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$8.42M
SLXN annual free cash flow is -$8.42 million

Free cash flow 1-year change

-85.38%
SLXN annual free cash flow is down -85.38% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
SLXN annual gross profit margin value is unknown

Operating margin

-
SLXN annual operating profit margin value is unknown

Net margin

-
SLXN annual net profit margin value is unknown

ROA & ROE

ROA

-574.33%
SLXN annual return on assets is -574.33%

ROE

412.21%
SLXN annual return on equity is 412.21%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
SLXN price to earnings ratio value is unknown

PE ratio Sector rank

-
SLXN price to earnings ratio is unknown

PB Ratio

PB ratio

-1.68
SLXN price to book ratio is -1.68

PB ratio Sector rank

6.75%
SLXN price to book ratio is higher than 6.75% of companies in Healthcare sector

PS Ratio

PS ratio

-
SLXN price to sales ratio value is unknown

PS ratio Sector rank

-
SLXN price to sales ratio is unknown

Enterprise value

Enterprise value

$10.01M
SLXN enterprise value is $10.01 million

Enterprise value Sector rank

25.27%
SLXN enterprise value is higher than 25.27% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.60
SLXN EV/EBITDA is -0.60

EV/EBITDA Sector rank

49.39%
SLXN EV/EBITDA is higher than 49.39% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

0.64
SLXN annual current ratio is 0.64

Quick ratio

-
SLXN annual quick ratio value is unknown

Leverage

Debt to equity

-1.13
SLXN annual debt to equity ratio is -1.13

Interest coverage ratio

-2357.43
SLXN annual interest coverage ratio is -2357.43

Risk & Stability

Piotroski F-Score

-
SLXN piotroski f-score value is unknown

Altman Z-Score

-
SLXN altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Mar 20, 25 Maxim Group
Buy
Nov 1, 24 Maxim Group
Buy

Institutional Ownership

Similar stocks

ZCMD logo
Zhongchao (ZCMD)
PPBT logo
Purple Biotech (PPBT)
EVGN logo
Evogene (EVGN)
CYCN logo
Cyclerion Therapeutics (CYCN)
PTN logo
Palatin Technologies (PTN)
SNGX logo
Soligenix (SNGX)
Apollomics (APLM)
INDP logo
Indaptus Therapeutics (INDP)
WORK Medical Technology Group LTD (WOK)
  • What is the ticker symbol for Silexion Therapeutics LTD?
  • Does Silexion Therapeutics LTD pay dividends?
  • What sector is Silexion Therapeutics LTD in?
  • What industry is Silexion Therapeutics LTD in?
  • What country is Silexion Therapeutics LTD based in?
  • When did Silexion Therapeutics LTD go public?
  • Is Silexion Therapeutics LTD in the S&P 500?
  • Is Silexion Therapeutics LTD in the NASDAQ 100?
  • Is Silexion Therapeutics LTD in the Dow Jones?
  • When does Silexion Therapeutics LTD report earnings?
  • Should I buy Silexion Therapeutics LTD stock now?

What is the ticker symbol for Silexion Therapeutics LTD?

The ticker symbol for Silexion Therapeutics LTD is NASDAQ:SLXN

Does Silexion Therapeutics LTD pay dividends?

No, Silexion Therapeutics LTD does not pay dividends

What sector is Silexion Therapeutics LTD in?

Silexion Therapeutics LTD is in the Healthcare sector

What industry is Silexion Therapeutics LTD in?

Silexion Therapeutics LTD is in the Biotechnology industry

What country is Silexion Therapeutics LTD based in?

Silexion Therapeutics LTD is headquartered in Israel

When did Silexion Therapeutics LTD go public?

Silexion Therapeutics LTD's initial public offering (IPO) was on August 16, 2024

Is Silexion Therapeutics LTD in the S&P 500?

No, Silexion Therapeutics LTD is not included in the S&P 500 index

Is Silexion Therapeutics LTD in the NASDAQ 100?

No, Silexion Therapeutics LTD is not included in the NASDAQ 100 index

Is Silexion Therapeutics LTD in the Dow Jones?

No, Silexion Therapeutics LTD is not included in the Dow Jones index

When does Silexion Therapeutics LTD report earnings?

The date for Silexion Therapeutics LTD's next earnings report has not been announced yet

Should I buy Silexion Therapeutics LTD stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page